<DOC>
	<DOCNO>NCT01452529</DOCNO>
	<brief_summary>The primary objective study evaluate analgesic efficacy safety HYD tablets 20 120 mg once-daily dose compare placebo subject moderate severe chronic low back pain uncontrolled current stable analgesic regimen</brief_summary>
	<brief_title>Efficacy Safety Hydrocodone Bitartrate ( HYD ) Subjects With Moderate Severe Chronic Low Back Pain</brief_title>
	<detailed_description />
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<mesh_term>Hydrocodone</mesh_term>
	<criteria>Inclusion Criteria include : Male female subject ≥ 18 year age moderate severe , chronic low back pain ( lasting several hour daily ) predominant pain condition least 3 month prior screen visit ; Subjects whose low back pain adequately treat prior screen visit stable incoming analgesic regimen ; Subjects deem investigator/medically qualify designee ( must MD DO ) appropriate candidate protocol specify , around clock HYD therapeutic regimen ; Female subject premenopausal postmenopausal less 1 year surgical sterilization ( ie , tubal ligation , partial complete hysterectomy ) must negative serum pregnancy test , nonlactating , willing use adequate reliable contraception throughout study ( eg , barrier additional spermicidal foam jelly , intrauterine device , hormonal contraception ) . Exclusion Criteria include : Subjects take &gt; 100 mg/day oxycodone equivalent last 14 day prior screen visit ; Subjects agree completely stop incoming opioid nonopioid analgesic medication medication use chronic pain , exclude herbal nutraceutical medication ; Subjects agree stop local regional pain treatment study ( nerve/plexus block ablation , neurosurgical procedure pain control , botulinum toxin injection control chronic low back pain , steroid injection low back inhalation analgesia ) . The subject must nerve/plexus block within 4 week screen visit , neuroablation within 6 month screen visit , botulinum toxin injection low back region within 3 month screen visit , steroid injection low back within 6 week screen visit , intravenous intramuscular steroid injection within 4 week screen visit ; Subjects use investigational medication within 30 day prior first dose study medication ; Subjects history seizure ( subject history pediatric febrile seizure may participate study ) increase intracranial pressure ; Subjects current uncontrolled depression uncontrolled psychiatric disorder ( subject control depression psychiatric disorder must stable medication ≥ 1 month prior screen visit participate study ) ; Subjects history alcohol , medication , illicit drug abuse addiction and/or history opioid abuse addiction time ; Subjects clinically unstable cardiac disease , include : unstable atrial fibrillation , symptomatic bradycardia , unstable congestive heart failure , active myocardial ischemia , indwell pacemaker ; Subjects unstable respiratory disease , opinion investigator , precludes entry study ; Subjects evidence impair liver function upon entry study ( laboratory test value ≥ 3 time upper limit laboratory reference ( normal ) range ( ULN ) aspartate transaminase [ AST/SGOT ] alanine transaminase [ ALT/SGPT ] , value &gt; 2 time ULN alkaline phosphatase ) , total bilirubin level &gt; 1.5 time ULN , opinion investigator/medically qualified designee ( must MD DO ) , liver function impairment extent subject participate study ; Subjects evidence impair kidney function upon entry study ( ie , serum creatinine ≥ 2.5 mg/dL ) ; Subjects biliary tract disease , hypothyroidism , adrenal cortical insufficiency , medical condition , opinion investigator , inadequately treat precludes entry study ; Subjects surgical procedure direct towards source chronic low back pain within 6 month screen visit schedule surgery lower back major surgery study conduct period ; Subjects history malignancy within past 2 year , exception basal cell carcinoma successfully treat ; Subjects condition opioids contraindicate , eg , severe respiratory depression hypoxia and/or hypercapnia , severe chronic obstructive lung disease , cor pulmonale , severe bronchial asthma , paralytic ileus ; Subjects allergic hydrocodone history allergy opioids . This include subject experienced common opioid side effect ( eg , nausea , constipation ) ; Subjects receive monoamine oxidase inhibitor ( MAOIs ) take MAOIs within 2 week screen visit . Other protocolspecific inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Pain</keyword>
	<keyword>Opioid</keyword>
</DOC>